-
Genomic Testing for Early Breast Cancer: Assessing the Value of Next-Generation Sequencing
Sep 9, 2025, 16:22 PM -
Healthcare Resource Utilization and Costs Among Bacillus Calmette-Guérin (BCG)-Experienced or Unresponsive Patients With Papillary-Only High-Risk Non–Muscle Invasive Bladder Cancer
Sep 9, 2025, 16:22 PM -
Bimekizumab Cost per Responder Analysis Compared to Other Licensed Interleukin Inhibitors at Week 52 for the Treatment of Psoriatic Arthritis: A United Kingdom Perspective
Sep 9, 2025, 16:22 PM -
Five-Year Inpatient Hospital Trends of COVID-19 Admissions in US Medicare Fee for Service
Sep 9, 2025, 16:22 PM -
Establishing Robust and Adaptive Willingness-to-Pay Thresholds for Taiwan's National Health Insurance: A Case Study of Non-Small Cell Lung Cancer
Sep 9, 2025, 16:22 PM -
Linking Data to Care: Mining the Pathways of Oncology
Sep 9, 2025, 16:22 PM -
The Innovative Licensing and Access Pathway (ILAP): Early Pathway Experience, Examining, Process Adaptations, and Industry Impact
Sep 9, 2025, 16:22 PM -
Examination of Muscle Activity Among Aesthetic Sports Athletes
Sep 9, 2025, 16:22 PM -
Patient Perspectives on the Lifelong Impact of Preterm Birth in Chronic Respiratory Disease Care
Sep 9, 2025, 16:22 PM -
Methods for Incidence Progression Estimation in Partitioned Survival Analysis: Does the Chosen Method Matter?
Sep 9, 2025, 16:22 PM -
Implementing SISAQOL Recommendations: Insights From Cancer Clinical Trials
Sep 9, 2025, 16:22 PM -
The Socioeconomic Burden of Dengue in Spain
Sep 9, 2025, 16:22 PM -
Optimizing a New Patient-Reported Outcome Instrument for Proliferative Diabetic Retinopathy: A Psychometric Study
Sep 9, 2025, 16:22 PM -
Economic Impact of Incorporating a Fecal Bacterial Signature to Optimize FIT-Based Colorectal Cancer Screening in Spain
Sep 9, 2025, 16:22 PM -
Development of an AI-Powered Tool to Accelerate and Enhance Systematic Literature Reviews for Evidence-Based Decision Making in Clinical Research
Sep 9, 2025, 16:22 PM -
Exit Strategies in Patients With Stable MS: Cost-Effectiveness of Extended Interval Dosing of Ocrelizumab and Natalizumab vs. De-escalating to Cladribine
Sep 9, 2025, 16:22 PM -
Fitting Flexible Survival Models to Landmark Survival Estimates in R
Sep 9, 2025, 16:22 PM -
The Perils of Treatment Crossover in Clinical Trials
Sep 9, 2025, 16:22 PM -
Medical Resource Utilizations and Economic Burden of Chemotherapy-Induced Anemia in Chinese Population: A Multicenter Retrospective Study
Sep 9, 2025, 16:22 PM -
The Uptake of R in NICE HTA: Insights From Technology Assessment Groups
Sep 9, 2025, 16:22 PM
